Amount Raised
$30 Million
Round Type
Series B
Menlo ParkBiotechnologyHealthcareInvestors
Description
Octave Bioscience, a leading precision care company focused on delivering a new standard of care for multiple sclerosis (MS) and other neurodegenerative diseases today announced the closing of a $30M extension to its Series B funding round. The round included participation from new strategic investors: Novartis (dRx Capital); Hikma Pharmaceuticals’ venture capital arm, Hikma Ventures; and Intermountain Ventures, as well as participation by all existing investors including The Blue Venture Fund, Echo Health Ventures, Section 32, Northpond Ventures, Deerfield Management, Casdin Capital, and Merck Global Health Innovation Fund. This funding will further accelerate commercialization efforts to bring Octave's multimodal solution to more multiple sclerosis patients.
Quick answer
Octave Bioscience raised $30 Million in a Series B round, dated July 26, 2023. Investors: Merck Global Health Innovation Fund, Casdin Capital, Deerfield Management, Northpond Ventures, Section 32, Echo Health Ventures, The Blue Venture Fund and Intermountain Ventures. Octave Bioscience is based in Menlo Park, California, United States.
- How much did Octave Bioscience raise?
- Octave Bioscience raised $30 Million in a Series B round on July 26, 2023.
- Who invested in Octave Bioscience?
- Merck Global Health Innovation Fund, Casdin Capital, Deerfield Management, Northpond Ventures, Section 32, Echo Health Ventures, The Blue Venture Fund and Intermountain Ventures are named as investors in this round.
- What does Octave Bioscience do?
- Octave Bioscience, Inc. is a commercial growth stage precision medicine company pioneering biomarker-driven solutions for neurodegenerative diseases, with an initial focus on Multiple Sclerosis, and Parkinson’s Disease..
- Where is Octave Bioscience based and how big is it?
- Octave Bioscience is based in Menlo Park, California, United States. Fundz records about 83 employees.
- Who are the decision-makers at Octave Bioscience?
- Fundz holds 2 contacts at Octave Bioscience, including the Director. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Healthcare and Biotechnology around the same time
Companies in the same sectors as Octave Bioscience that raised within 45 days of this round, from Fundz verified event records.
- Cellectar raised $25M on September 8, 2023.
- HeartSciences raised $1M (Seed) on September 7, 2023.
- Arthrosi Therapeutics raised $7M on September 5, 2023.
- Cellectar raised $103M (Post-IPO Equity) on September 5, 2023.
- Cardio Flow, Inc. raised $100K (Seed) on September 1, 2023.
- Beta Bionics raised $99M on August 28, 2023.
Who to call at Octave Bioscience, and when
A new round usually means Octave Bioscience is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Octave Bioscience raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Octave Bioscience, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Octave Bioscience. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Octave Bioscience raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansOctave Bioscience raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.